Our first orbital platform in low Earth orbit — a new approach to LEO Commercialization.

ST-42, Space Tango’s first orbital platform, aims to harness the unique environment of microgravity to produce high value products across industries; from patient therapeutics to advanced technology products that have the potential to revolutionize industries here on Earth.

Launching in the mid-2020s, ST-42’s initial design will incorporate features that address Current Good Manufacturing Practice (CGMP). These regulations are enforced by the FDA and are a critical component in the production of patient therapeutics that Space Tango intends to establish as a capability on orbit within the platform. Coupling autonomous manufacturing capabilities with reduced cost and adaptability for various launch vehicle providers, ST-42 intends to be at the forefront of developing new biomedical and technology sectors in the commercial Space economy.

Learn More about ST-42 Here